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Abstract
Background: Since sarcopenia is an important risk factor for falls or cardiovascular disease, early detection and
prevention of sarcopenia are being increasingly emphasized. Emerging evidence has indicated relationships
between sarcopenia, insulin resistance, and inflammation. The triglyceride glucose (TyG) index, a novel surrogate
marker of insulin resistance and systemic inflammation, has not yet been shown to be associated with sarcopenia.
This study aimed to examine the relationship between the TyG index and muscle mass in Korean adults.
Methods: This study included 15,741 non-diabetic adults over 19 years old using data from the 2008–2011 Korea
National Health and Nutrition Examination Survey. Participants were divided into three groups according to tertiles
of the TyG index. A low skeletal muscle mass index (LSMI) was defined by the Foundation for the National Institutes
of Health Sarcopenia Project criteria. A weighted multivariate logistic regression model was used to analyze
relationships between TyG index tertiles and LSMI.
Results: The ORs (95% CIs) for LSMI in the second and third TyG tertiles, compared to the first tertile, were 1.463 (1.131–
1.892) and 1.816 (1.394–2.366), respectively, after adjusting for confounding factors. Higher TyG index values were also
associated with increased odds of LSMI in adults under 65 years who did not exercise regularly, who consumed less than
30 g of alcohol per day, who did not currently smoke, and who ate less than 1.5 g of protein/kg/day.
Conclusion: The TyG index was significantly and positively associated with LSMI in Korean adults.
Keywords: Triglyceride and glucose index, Sarcopenia, Low skeletal muscle index, Public health, Insulin resistance,
Chronic inflammation, Inflammatory cytokines, Metabolic syndrome
Introduction
Sarcopenia is defined as an unintentional decline in
muscle mass, strength, and performance that arises with
aging [1]. However, there are no unified criteria for diag-
nosing sarcopenia [2–5]. Typically, muscle mass reduces
by 3–8% per decade after the age of 30, and muscle
strength [6, 7], a major part of physical function,
decreases by 1–2% per year after 50 years of age [8, 9].
For this reason, sarcopenia is mainly observed in older
adults, although it can also occur in younger adults [10].
The estimated prevalence of sarcopenia has been re-
ported to be at least 4.6% in all older adults and nearly
25% in older hospitalized patients [11]. Sarcopenia has
become an increasingly important issue in public health
as life spans have increased [12, 13]. Indeed, healthcare
costs related to sarcopenia were reported to be $18.5 bil-
lion ($10.8 billion in men, $7.7 billion in women) in the
United States in 2000, constituting about 1.5% of total
healthcare expenditures for the year [13, 14].
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Sarcopenia is associated not only to increased risks of
falls, fractures, and disabilities [15, 16], but also to meta-
bolic disorders, such as insulin resistance, type 2 dia-
betes mellitus, dyslipidemia, and hypertension [17], as a
result of decreases in basal metabolic rate, fat-free mass,
and physical activity. Additionally, sarcopenia has been
shown to be associated with chronic, low-grade, systemic
inflammation [18–21], and several reports have de-
scribed a relationship between sarcopenia, insulin resist-
ance [22], and inflammation [23].
The triglyceride and glucose index (TyG index), a
product of triglyceride levels and fasting plasma glucose
concentration, has recently been recognized as a useful
clinical surrogate marker of insulin resistance [24, 25]
and systemic inflammation [26, 27]. Moreover, the TyG
index has been validated for predicting the risk of dia-
betes and cardiovascular disease syndrome [28–32], as
well as for diagnosing metabolic syndrome [33]. How-
ever, to date there have been no studies of the relation-
ship between the TyG index and sarcopenia. In this
analysis, we investigated the association between TyG




All study data were obtained from the 2008–2011 Korea
National Health and Nutrition Examination Survey
(KNHANES), a nationwide representative survey con-
ducted by the Korea Centers for Disease Control and
Prevention to assess the health and nutritional status of
Koreans. The KNHANES employs a cross-sectional,
stratified, multistage, probability sampling design based
on age, sex, and geographical area. Sample weights were
assigned to subjects to capture a sample representing
the general Korean population. Survey items in the
KNHANES have been revised partially because of the
availability of survey resources, and some questionnaires
have been updated and changed over the years [34]. De-
tailed methods related to the KNHANES have been pre-
viously described [34].
A total 37,753 of individuals participated in the 2008–
2011 KNHANES. Of these participants, we excluded 1)
those who were under 19 years old (n = 9736), 2) those
missing serum glucose level data (n = 2772), 3) those
who did not report history of type 2 diabetes mellitus
(n = 937), 4) those diagnosed type 2 diabetes mellitus by
a doctor, treated with anti-diabetic medications, or
treated with insulin (n = 917), 5) those who had fasting
plasma glucose levels 126 mg/dL or more (n = 1551), 6)
those missing body mass index (BMI) data (n = 89), 7)
those missing serum triglyceride level data (n = 1), or 8)
those missing whole-body dual-energy X-ray absorpti-
ometry (DXA) data (n = 6369). Finally, a total of 15,741
participants (6646 men and 9095 women) were included
in this analysis (Fig. 1).
Biochemical measurements
Blood samples were collected from the antecubital vein
from each patient after at least 8 h of fasting. Serum total
Fig. 1 Flowchart of study population selection
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cholesterol, triglycerides, high-density lipoprotein (HDL)
cholesterol, and plasma glucose concentrations were
measured using a Hitachi 7600 Analyzer. White blood
cell (WBC) counts were analyzed using a XE-2100D
blood cell counter. The TyG index was calculated as fol-
lows: log [serum triglycerides (mg/dL) × plasma glucose
(mg/dL)/2]. At present, there is no reference value for
the prediction of sarcopenia using the TyG index.
Therefore, we divided participants into three groups ac-
cording to tertiles of the TyG index: T1 (6.45–8.19), T2
(8.20–8.71), and T3 (8.72–11.29).
Assessment of muscle mass
DXA was performed from July 2008 to June 2011 to
evaluate body composition (QDR 4500A; Hologic Inc.,
Bedford, MA, USA). Body composition data were ob-
tained from predefined anatomical areas as follows:
head, arms, legs, trunk, pelvic region, and whole body.
Participants were analyzed for bone mineral content (g),
bone mineral density (g/cm2), fat mass (g), lean body
mass (g), and total fat percentage (fat mass/total mass ×
100). Skeletal muscle mass was calculated using the fol-
lowing equation: lean body mass (g) - bone mineral con-
tent (g). Appendicular skeletal muscle mass (ASM) was
calculated as the summation of the skeletal muscle mass
of both upper and lower extremities. We defined the
skeletal muscle mass index (SMI) as ASM (kg) divided
by body mass index (BMI) (kg/m2). Finally, the low skel-
etal muscle index (LSMI) was defined according to the
Foundation for the National Institutes of Health (FNIH)
Sarcopenia Project criteria: SMI values less than 0.789
for men and less than 0.512 for women [5].
Measurement of anthropometric and clinical parameters
Height (cm) and body weight (kg) were estimated to the
nearest 0.1 cm using a stadiometer without shoes in a
standing posture or supine position and to the nearest
0.1 kg using digital scale in light clothing, respectively.
BMI was calculated as body weight divided by height
squared (kg/m2). Adults with a BMI greater than or
equal to 25 kg/m2 were considered overweight and those
with a BMI less than 18.5 kg/m2 were considered under-
weight according to the guidelines of the International
Obesity Task Force of the World Health Organization
[35]. Adults were categorized into three different cat-
egories of smoking status: current smokers, ex-smokers,
and never smokers. We defined a current smoker as
someone who smoked at the time of the interview and
had smoked at least 100 cigarettes over their lifetime.
Ex-smokers were defined as those who did not currently
smoke, but who had smoked at least 100 cigarettes in
his or her lifetime. Heavy alcohol use was defined as
consuming an average of 30 g or more of alcohol per
day. We defined regular exercise as 20 min of vigorous
exercise at least 3 days per week or 30min of moderate
exercise/walking at least 5 days per week, and physical
activity was assessed using the International Physical Ac-
tivity Questionnaire (IPAQ). A food frequency question-
naire (FFQ) was used for all adults aged 19 years or
older. Daily nutritional intake of total calorie (kcal/day),
carbohydrate (CHO) (g/day), fat (g/day), and protein (g/
day) were surveyed. Based on the modified NCEP ATP-
III criteria [36], this study defined metabolic syndrome
according to the following criteria: (1) waist circumfer-
ence ≥ 90 cm in men and ≥ 85 cm in women, per the
Korean-specific cut-offs for abdominal obesity of the Ko-
rean Society of Obesity [37]; (2) serum triglycerides
≥150 mg/dL; (3) either fasting plasma glucose ≥100 mg/
dL, the use of anti-diabetic medications, or current treat-
ment with insulin therapy; (4) HDL cholesterol < 40 mg/
dL in men or < 50mg/dL in women or use of lipid-
lowering medications; and (5) blood pressure ≥ 130/85
mmHg or use of anti-hypertensive medications. Detailed
information about the KNHANES is available on the
KNHANES website (http://knhanes.cdc.go.kr).
Statistical analysis
All data are presented as a mean or percentage (%) ±
standard error (SE). For the analysis of clinical charac-
teristics of the study population, a weighted analysis of
variance (ANOVA) test was used for continuous vari-
ables, followed by post-hoc analysis with Bonferroni cor-
rection. For categorical variables, weighted chi-square
tests were used to analyze differences among the three
groups, followed by post-hoc analysis with Bonferroni
correction. After adjusting for confounding variables, a
weighted multivariate logistic regression analysis was
performed to calculate odds ratios (ORs) with 95% confi-
dence intervals (CIs) for LSMI according to the TyG
index tertiles. We further analyzed subgroups according
to age, alcohol drinking status, smoking status, amount
of protein intake, and regular exercise through a
weighted multivariate logistic regression analysis. All
statistical analyses were conducted using SPSS statistical
software (version 25.0; SPSS Inc., Chicago, IL, USA).
The significance level was set at p less than 0.05.
Results
General characteristics of the study population
Table 1 presents the clinical characteristics of 15,741
subjects according to tertiles of the TyG index. The pro-
portions of men and mean age were lowest in T1 and
highest in T3. The mean values of waist circumference,
BMI, mean blood pressure, blood leukocyte count, fast-
ing plasma glucose levels, serum total cholesterol levels,
and log-transformed triglyceride levels increased,
whereas HDL cholesterol levels decreased with each in-
crease in TyG index tertile. The proportions of heavy
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alcohol drinkers, current smokers, and number of
chronic diseases increased along with TyG index tertiles.
The proportion of adults participating in regular exercise
was highest in T1 and lowest in T3, although these
trends were not statistically significant. The average
amounts of daily calorie intake, carbohydrate intake, and
protein intake significantly increased with increasing
TyG index tertiles, while the amount of daily fat intake
decreased with increasing TyG index tertiles. The mean
values of SMI decreased with increasing TyG index
tertiles for both men and women. The prevalence of
LSMI increased with increasing TyG index tertiles
(Fig. 2). The number of components of metabolic syn-
drome was higher in T3 than T1. WBC counts increased
with an increase in the TyG index tertiles.
Association between TyG index and LSMI
Table 2 shows the results of multivariate logistic regres-
sion analysis, including the ORs (95% CIs) for LSMI ac-
cording to the TyG index tertiles. The OR (95% CIs) for
Table 1 Clinical characteristics of three different population
TyG index 2008–2011 KNHANES
T1 T2 T3 Total p for trend
6.45–8.19 8.20–8.71 8.72–11.29
Unweighted number 5229 5235 5277 15,741
Male sex,n(%) 1520 (29.1) 2193 (41.9) 2933 (55.6) 6641 (42.2) < 0.001
Age, years 38.3 ± 0.3a 44.3 ± 0.3b 47.7 ± 0.3c 43.4 ± 0.2 < 0.001
Waist circumference, cm 75.2 ± 0.2a 80.2 ± 0.2b 85.5 ± 0.2c 80.3 ± 0.1 < 0.001
Body weight, kg 59.1 ± 0.2a 63.4 ± 0.2b 68.2 ± 0.2c 63.6 ± 0.1 < 0.001
Mean blood pressure, mmHg 85.4 ± 0.2a 90.3 ± 0.3b 94.5 ± 0.3c 90.1 ± 0.2 < 0.001
Leukocyte count (*1000/μL) 5.6 ± 0.0a 6.0 ± 0.0b 6.6 ± 0.0c 6.1 ± 0.0 < 0.001
Glucose, mg/dL 88.0 ± 0.1a 92.2 ± 0.2b 96.9 ± 0.2c 92.3 ± 0.1 < 0.001
Log-transformed Triglyceride, mg/dL 4.0 ± 0.0a 4.6 ± 0.0b 5.3 ± 0.0c 4.7 ± 0.0 < 0.001
Employment status, % (SE) 63.6 (0.9)a 62.9 (1.0)a 68.1 (0.9)c 64.8 (0.6) < 0.001
Heavy alcohol use, % (SE) 5.2 (0.5)a 7.5 (0.5)b 13.8 (0.7)c 8.8 (0.3) < 0.001
Current smoker, % (SE) 18.5 (0.8)a 25.3 (0.9)b 38.0 (1.0)c 27.0 (0.6) < 0.001
Regular exercise, % (SE) 25.5 (0.8)a 25.4 (0.8)a 24.0 (0.8)a 25.0 (0.5) 0.307
Daily calorie intake, kcal/day 1982.3 ± 16.5a 2010.0 ± 17.3a 2125.7 ± 20.1c 2039.3 ± 11.1 < 0.001
Daily protein intake, % of total calorie intake 14.6 ± 0.1a 14.4 ± 0.1a 14.2 ± 0.1b 14.4 ± 0.1 0.001
SMI
Men 1.006 ± 0.004a 0.963 ± 0.004b 0.921 ± 0.003c 0.963 ± 0.002 < 0.001
Women 0.666 ± 0.002a 0.629 ± 0.002b 0.596 ± 0.002c 0.631 ± 0.002 < 0.001
Number of components of metabolic syndrome < 0.001
0 56.3 (0.9)a 30.9 (0.9)b 3.4 (0.4)c 30.6 (0.5)
1 33.0 (0.8)a 39.5 (0.9)b 15.4 (0.7)c 29.3 (0.5)
2 8.4 (0.5)a 20.0 (0.7)b 29.8 (0.9)c 19.2 (0.4)
3 2.0 (0.2)a 8.3 (0.4)b 28.9 (0.9)c 12.9 (0.4)
4 0.2 (0.1)a 1.3 (0.2)b 17.8 (0.6)c 6.3 (0.2)
5 – – 4.8 (0.3) 1.6 (0.1)
Number of chronic diseases, % (SE) < 0.001
0 95.6 (0.4)a 93.1 (0.4)b 92.1 (0.5)b 93.5 (0.3)
1 4.0 (0.3)a 6.2 (0.4)b 7.2 (0.4)b 5.8 (0.2)
≥ 2 0.4 (0.1)a 0.7 (0.1)b 0.7 (0.1)b 0.6 (0.1)
Abbreviations: TyG index triglyceride-glucose index, KNHANES Korean National Health and Nutrition Examination Survey, SE standard error, BMI body mass index,
SMI skeletal muscle mass index
p for trend was derived from weighted generalized linear regression analysis for continuous variables, followed by post-hoc analysis with Bonferroni correction
and weighted chi-square test for linear-by-linear association for categorical variables, followed by post-hoc analysis with Bonferroni correction.
Superscripts (a b c), for a particular variable, indicate significant difference between tertiles (p < 0.0167). Variables with the same superscripts are not significantly
different (p > 0.0167). When only one comparison was significant, one of the cell means has no superscript attached.
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Fig. 2 Prevalence of LSMI according to TyG index tertiles
Table 2 Association between TyG index and LSMI
TyG index tertile Sample size of LSMI, n (%) B SE ORs 95% CIs Wald p Overall p p for trend
Unadjusted 79.670 < 0.001 < 0.001
T1 228 (4.4) Ref. Ref. 1 (Ref.) Ref. Ref.
T2 446 (8.5) 0.799 79.67 2.223 1.781–2.776 < 0.001
T3 712 (13.5) 1.267 0.103 3.549 2.897–4.347 < 0.001
Model 1 28.277 < 0.001 < 0.001
T1 228 (4.4) Ref. Ref. 1 (Ref.) Ref. Ref.
T2 446 (8.5) 0.482 0.121 1.619 1.277–2.053 < 0.001
T3 712 (13.5) 0.831 0.116 2.296 1.829–2.881 < 0.001
Model 2 14.880 < 0.001 < 0.001
T1 228 (4.4) Ref. Ref. 1 (Ref.) Ref. Ref.
T2 446 (8.5) 0.434 0.130 1.544 1.195–1.994 0.001
T3 712 (13.5) 0.711 0.133 2.037 1.569–2.645 < 0.001
Model 3 10.809 < 0.001 < 0.001
T1 228 (4.4) Ref. Ref. 1 (Ref.) Ref. Ref.
T2 446 (8.5) 0.399 0.131 1.491 1.152–1.930 0.002
T3 712 (13.5) 0.629 0.137 1.876 1.434–2.454 < 0.001
Model 4 10.013 < 0.001 < 0.001
T1 228 (4.4) Ref. Ref. 1 (Ref.) Ref. Ref.
T2 446 (8.5) 0.380 0.131 1.463 1.131–1.892 0.004
T3 712 (13.5) 0.597 0.135 1.816 1.394–2.366 < 0.001
Abbreviations: TyG index triglyceride-glucose index, LSMI low skeletal muscle mass index, ORs odds ratio, CIs confidence intervals
Model 1: Adjusted for age, sex, body weight, and regular exercise.
Model 2: Adjusted for variables included in Model 1 plus employment status, alcohol use, smoking status, daily protein intake, number of chronic diseases, and
serum total cholesterol level.
Model 3: Adjusted for variables included in Model 2 plus plasma glucose level.
Model 4: Adjusted for variables included in Model 3 plus mean blood pressure./
SMI was defined using the following equation: ASM (kg)/BMI (kg/m2).
We defined the LSMI according to the cut-off value of SMI based on the Foundation for the National Institutes of Health (FNIH) sarcopenia project criteria: SMI less
than 0.789 for men and SMI less than 0.512 for women.
The odds ratio and 95% confidence interval were calculated using the weighted multi-variate logistic regression analysis to evaluate the relationship between TyG
index and LSMI.
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LSMI in T3 of the TyG index versus T1 was 3.549
(2.897–4.347). This relationship remained significant
after adjusting for age, sex, body weight, regular ex-
ercise, employment status, heavy alcohol use, smok-
ing status, daily protein intake, number of chronic
diseases, total cholesterol level, plasma glucose level,
and mean blood pressure (T3 vs. T1, ORs = 1.816,
95% CIs: 1.394–2.366, p < 0.001).
Table 3 presents the results of subgroup analysis
showing the relationship between TyG index and LSMI.
The fully adjusted ORs (95% CIs) for LSMI in T3 com-
pared to T1 were significant in both sex, adults under
65 years of age, both regular and irregular exercising
groups, adults with normal body weight, drinking alco-
hol less than 30 g per day group, both current smokers
and non-current smokers, both adults who consumed
1.5 g per kg of protein or more per day and adults who
consumed less than 1.5 g per kg of protein per day.
There were no significant differences between groups
among adults over 65 years of age, underweight adults,
overweight adults, and heavy alcohol drinkers.
Each P was calculated by multivariate logistic regres-
sion analysis after adjusting for all confounders (age, sex,
body weight, regular exercise, employment status, alco-
hol use, smoking status, daily protein intake, number of
chronic diseases, serum total cholesterol level, and
plasma glucose level, and mean blood pressure), except
for the variable used in each subgroup analysis.
Discussion
The prevention of frailty is an important strategy
through which to address related comorbidities, such as
falls, cardiovascular events, cognitive impairment, and
mortality [38, 39]. The cycle of frailty consists of four
main components: reduced resting metabolic rate, de-
creased total energy expenditure, chronic undernutri-
tion, and sarcopenia [40]. Of these, sarcopenia is of
particular importance to enabling activities of daily liv-
ing, preventing falls, and reducing various metabolic dis-
eases [39, 40]. Therefore, methods for the early
detection and prevention of sarcopenia would be of clin-
ical and societal value.
In this study, adults of both sexes who had higher TyG
index values were more likely to have LSMI, even after
adjusting for age and other confounding factors. These
findings were based on data from a representative,





p overall p p for trend
Sex
Men 1 (Ref.) 1. 485 (0.969–2.275) 0.069 2.138 (1.377–3.319) 0.001 0.001 < 0.001
Women 1 (Ref.) 1.415 (1.068–1.874) 0.016 1.620 (1.189–2.207) 0.002 0.010 0.003
Age groups
< 65 1 (Ref.) 1.864 (1.363–2.549) < 0.001 2.691 (1.947–3.719) < 0.001 < 0.001 < 0.001
≥ 65 1 (Ref.) 1.177 (0.823–1.683) 0.371 1.333 (0.940–1.889) 0.107 0.248 0.095
Regular exercise
Yes 1 (Ref.) 1.628 (0.925–2.866) 0.091 1.862 (1.074–3.229) 0.027 0.087 0.027
No 1 (Ref.) 1.400 (1.068–1.833) 0.015 1.795 (1.352–2.384) < 0.001 < 0.001 < 0.001
Weight status
Underweight 1 (Ref.) 1.201 (0.205–7.027) 0.839 0.085 (0.005–1.432) 0.087 0.228 0.132
Normal 1 (Ref.) 1.412 (1.018–1.959) 0.039 1.568 (1.085–2.266) 0.017 0.050 0.021
Overweight 1 (Ref.) 0.990 (0.685–1.430) 0.957 1.060 (0.747–1.505) 0.743 0.835 0.621
Heavy alcoholics
< 30 g/day 1 (Ref.) 1.535 (1.206–1.954) 0.001 1.897 (1.470–2.448) < 0.001 < 0.001 < 0.001
≥ 30 g/day 1 (Ref.) 0.334 (0.088–1.266) 0.107 0.668 (0.180–2.483) 0.547 0.133 0.997
Current smoker
Yes 1 (Ref.) 1.167 (0.624–2.183) 0.629 2.097 (1.096–4.012) 0.025 0.009 0.008
No 1 (Ref.) 1.536 (1.190–1.983) 0.001 1.775 (1.363–2.313) < 0.001 < 0.001 < 0.001
Protein intake
> 1.5 g/kg/day 1 (Ref.) 1.133 (0.582–2.202) 0.713 2.160 (1.132–4.121) 0.020 0.008 0.010
≤ 1.5 g/kg/day 1 (Ref.) 1.515 (1.151–1.995) 0.003 1.816 (1.361–2.423) < 0.001 < 0.001 < 0.001
Abbreviations: TyG index triglyceride-glucose index, LSMI low skeletal muscle mass index, ORs odds ratios, CIs confidence intervals
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nationwide, cross-sectional survey. The exact mechan-
ism by which TyG index is positively associated with
LSMI is not known, although we hypothesize that insu-
lin resistance and chronic inflammation may be the
major links between elevated TyG index and an in-
creased risk of sarcopenia. The pathogenesis of sarcope-
nia has been suggested to be closely related to chronic
inflammation [20], which consequently increases insulin
resistance [41], and may be reflected as an increased
TyG index. The TyG index is thought to represent insu-
lin resistance because it is calculated on the basis of two
metabolic parameters: serum triglycerides and fasting
glucose. Although we could not directly investigate the
association between TyG index and insulin resistance
index due to a lack of insulin data in the 2008–2011
KNHANES, we did find that the TyG index was related
to the severity of metabolic syndrome, which is closely
associated with insulin resistance [24, 42]. In addition,
we found that a higher TyG index was associated with
higher blood leukocyte count, a marker of chronic in-
flammation [43].
Sarcopenia is accompanied by muscle fat accumulation
and an increase in pro-inflammatory cytokines, such as
interleukin-6 (IL-6) and tissue necrosis factor alpha (TNF-
α) within myocytes [44, 45], which contribute to subse-
quent decreases in muscle mass and strength [46, 47]. IL-
6 downregulates glucose transporter 4 expression and in-
sulin receptor substrate-1 (IRS-1), resulting in reduced
transport of glucose into cells (including myocytes) and
aggravation of insulin resistance [48]. TNF-α initiates a
wide range of downstream signaling cascades, such as the
activation of nuclear factor kappa B (NF-κB) and c-Jun N-
terminal kinase (JNK) [49, 50]. In turn, NF-κB and JNK
lead to the impairment of IRS-1 and aggravation of insulin
resistance [49]. Moreover, upregulated NF-κB caused by
pro-inflammatory cascades causes ubiquitination of
muscle proteins and dissociation of actin and myosin fila-
ments, which consequently leads to further loss of skeletal
muscle [51, 52].
In subgroup analysis, the TyG index was independ-
ently related to LSMI regardless of the presence of sev-
eral risk factors for sarcopenia, such as sex, smoking
status, and protein intake status [53–55]. When we di-
vided study subjects according to age, adults under 65
years had higher odds of LSMI with increasing higher
TyG index tertile; however, there was no relationship be-
tween TyG index and LSMI in adults over 65 years of
age. Although we could not explain the exact cause, the
different percentage of participants with at least one
chronic disease could account for the difference between
younger and old adults (4.2% in younger adults group vs.
21.3% in older adult group). Regular exercise has positive
effects on muscle mass and decrease insulin resistance
and chronic inflammation [56, 57]. In our study, the
regular exercise group showed a weakened relationship
between TyG and LSMI (overall P = 0.087), compared to
the non-regular exercise group. However, the ORs for
LSMI showed consistent linearity with increases in TyG
index tertile in both groups (P for trend = 0.027, <
0.001). Because the IPAQ does not provide information
on the timing of exercise and or type/duration of phys-
ical activity, further research is needed with more de-
tailed information on physical activity.
The relationship between the TyG index and LSMI
was only significant in the normal alcohol consumption
group (< 30 g/day). Prior evidence has suggested that
heavy alcohol drinking may accelerate sarcopenia [58],
and it may interfere with the relationship between TyG
index and LSMI in the excessive consumption group
(≥30 g/day). When we divided the study group according
to BMI, only the normal weight group showed a signifi-
cant relationship between TyG index tertile and LSMI.
Obese people are at risk for being exposed to oxidative
stress and chronic inflammation [59], and this chronic
inflammatory status could contribute to TyG index values
in various ways, such as glucose uptake and adipokine se-
cretion [60, 61]. The number of individuals in the under-
weight group was small, and small sample size could act
as confounding factor in the statistical analysis. Further re-
search with a larger number of study participants would
be helpful to elucidating the relationship between TyG
index and LSMI in underweight individuals.
Unlike aging, alcohol drinking, exercise, underweight,
and obesity are modifiable risk factors. Therefore, redu-
cing alcohol consumption, regular exercising, and main-
taining normal weight could be priority strategies to
preventing LSMI.
Strengths and limitations
This is the first study to confirm a relationship between
the TyG index and muscle mass through the use of
DXA and a representative, nationwide dataset from Ko-
rean adults. However, this study had several limitations.
First, data on muscle mass information was only col-
lected; this study could not obtain muscle strength or
performance data, precluding a direct diagnosis of sarco-
penia among the adults. Second, the study could not
compare TyG index values with insulin resistance index
values, such as homeostatic model assessment for insulin
resistance. Finally, due to the cross-sectional study de-
sign, we could not assess causality between TyG index
and LSMI.
Conclusion
In conclusion, this study found that the TyG index is in-
dependently and negatively associated with LSMI in Ko-
rean adults over 19 years old. Because the TyG index
can be easily measured in clinical settings through blood
Ahn et al. Lipids in Health and Disease          (2020) 19:243 Page 7 of 9
sampling, this may serve as a helpful method for the
early detection of sarcopenia and related comorbidities,
thus enabling timely initiation of treatment and reduced
social, healthcare expenditures for treating sarcopenia.
Longitudinal cohort studies and exploratory studies are
needed to investigate the relationship between the TyG
index and sarcopenia.
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